

CORRECTION

Correction: SHCBP1 a potential target in ovarian cancer growth and stemness

Dongdong Li¹, Liping Wang^{2,*}¹Graduate School, Guangxi University of Chinese Medicine, 530200 Nanning, Guangxi, China²Reproductive Medicine Centre, Shenzhen Second People's Hospital, 518035 Shenzhen, Guangdong, China***Correspondence**

lpwang1385@163.com (Liping Wang)

In the original publication [1] of the above article, references [15], [20], [24], [28], and [29] were cited incorrectly. The correct citations should be:

[15] La Vecchia C. Ovarian cancer: epidemiology and risk factors. *European Journal of Cancer Prevention*. 2017; 26: 55–62.

[20] Friedrich M, Friedrich D, Kraft C, Rogmans C. Multimodal treatment of primary advanced ovarian cancer. *Anti-cancer Research*. 2021; 41: 3253–3260.

[24] Jiang F, Shi Y, Wang Y, Ge C, Zhu J, Fang H, *et al.* Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets. *Aging*. 2023; 15: 2066–2081.

[28] Wang C, Chen Q, Xu H. Wnt/ β -catenin signal transduc-

tion pathway in prostate cancer and associated drug resistance. *Discover Oncology*. 2021; 12: 40.

[29] Yu S, Han R, Gan R. The Wnt/ β -catenin signalling pathway in haematological neoplasms. *Biomarker Research*. 2022; 10: 74.

The authors confirm that these corrections do not affect the scientific conclusions or the overall validity of the article. The authors apologize for any inconvenience caused to the readers and the journal.

References

- [1] Li DD, Wang LP. SHCBP1 a potential target in ovarian cancer growth and stemness. *European Journal of Gynaecological Oncology*. 2025; 46: 142–149.